Rafael Holdings (NYSE: RFL) shares fell 33.17% in pre-market trading after the company announced topline results from its pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo in Niemann-Pick Disease Type C. The stock dropped to $1.37 from the previous regular-session close of $2.05, with approximately 240,986 shares changing hands in the session.
What happened
Rafael Holdings issued a press release on September 30, 2026 via GlobeNewsWire announcing topline results from the pivotal Phase 3 TransportNPC study of Trappsol Cyclo in Niemann-Pick Disease Type C. The company stated the trial had reached its primary endpoint, though investor reaction to the full dataset proved negative, triggering the sharp pre-market decline.
Why the stock moved
The market responded negatively to the Phase 3 readout despite Rafael Holdings characterizing the results as achieving the study's primary endpoint. Clinical trials for rare disease treatments often face high scrutiny on safety profiles and magnitude of benefit. Investors appeared to conclude that the data did not support a compelling commercial opportunity, prompting aggressive selling in pre-market trading. The stock had gained 1.49% during regular trading hours on September 30 before the announcement, then reversed sharply in after-hours and pre-market action following the release.
The numbers
Pre-market activity showed RFL at $1.37, down $0.68 from the prior close of $2.05. Trading volume reached 240,986 shares. The company's market capitalization stands at approximately $50.35 million. Short interest is 791,280 shares with 6.82 days to cover based on average daily volume of 116,057 shares. The float contains 25,214,873 shares out of 36,750,000 total shares outstanding.
What to watch
Rafael Holdings has not yet indicated whether it plans to pursue a regulatory filing with the FDA based on the TransportNPC results or conduct additional studies. The company's lead drug candidate remains CPI-613 (devimistat), which continues in two Phase III registrational trials for metastatic pancreatic cancer and relapsed/refractory acute myeloid leukemia. Those ongoing Phase 3 trials represent potential catalysts for the company going forward. Any update from the company regarding next steps for Trappsol Cyclo will likely influence the stock's near-term direction.